Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | TGFB1 | P01137 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22910469 | 0.91 | TGFBR1 (0.52) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL23330008 | 0.91 | TGFBR1 (0.52) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL23347282 | 0.91 | TGFBR1 (0.54) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL23347239 | 0.90 | TGFBR1 (0.59) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL23347212 | 0.89 | TGFBR1 (0.58) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL23347201 | 0.89 | TGFBR1 (0.62) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL23347298 | 0.88 | TGFBR1 (0.62) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL23347245 | 0.88 | TGFBR1 (0.55) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL21447719 | 0.88 | TGFBR1 (0.55) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL23347273 | 0.86 | TGFBR1 (0.60) | TGFBR1MAPK14RIPK2TGFB1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | TGFBR1 36/4885MAPK14 2693/4885RIPK2 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.